MajesTEC-1: update on RP2D of teclistamab in R/R myeloma

Amrita Krishnan, MD, City of Hope, Duarte, CA, shares an update on the Phase I MajesTEC-1 study (NCT03145181) of teclistamab, an IgG4 bispecific antibody which targets BCMA and CD3, in patients with relapsed/refractory myeloma. Dr Krishnan reports that teclistamab was well-tolerated with mild cytopenias and neurotoxicity and grade one or grade two cytokine release syndrome. The overall response rate among evaluable patients treated at the recommended Phase II dose (RP2D) (n=40) was 65%, with 58% achieving a very good partial response or better, and 30% achieving a complete response or better. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.